Widespread of ESBL- and carbapenemase GES-type genes on carbapenem-resistant Pseudomonas aeruginosa clinical isolates: a multicenter study in Mexican hospitals

Garza–Ramos, Ulises; Barrios, H.; Reyna-Flores, Fernando; Tamayo-Legorreta, Elsa; Catalán-Nájera, Juan Carlos; Morfín‐Otero, Rayo; Rodríguez-Noriega, Eduardo; Volkow, Patricia; Cornejo‐Juárez, Patricia; Gonzalez, Alejandra; Gaytán-Martı́nez, Jesús; Gónzalez-Martínez, Marisela del Rocío; Vazquez-Farias, Maria; Silva-Sánchez, Jesús

doi:10.1016/j.diagmicrobio.2014.09.029

Cited by 43 publications

(26 citation statements)

References 16 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Carbapenem-nonsusceptible isolates without MBLs, such as those carrying KPC (12)(13)(14)32) or OXA-48-like (13,32) carbapenemases, were generally susceptible to ceftazidimeavibactam ( (35); however, we identified only one isolate carrying bla SPM , collected in Brazil, in the current study. PER-and GES-type ␤-lactamases were heavily represented in P. aeruginosa isolates collected in Latin America, especially in isolates from Mexico (as reported previously [36]). Although MBL-negative subsets of ESBL-and GES-producing isolates showed reduced susceptibility to ceftazidime-avibactam, the enzyme variants found in these isolates are expected to be susceptible to inhibition by avibactam (37), suggesting the presence of additional undetermined resistance mechanisms.…”

Section: Discussionsupporting

confidence: 74%

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015

Karlowsky¹,

Kazmierczak²,

Bouchillon³

et al. 2019

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The International Network for Optimal Resistance Monitoring (INFORM) global surveillance program collected clinical isolates of Enterobacteriaceae (n ϭ 7,665) and Pseudomonas aeruginosa (n ϭ 1,794) from 26 medical centers in six Latin American countries from 2012 to 2015. The in vitro activity of ceftazidime-avibactam and comparators was determined for the isolates using the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method. Enterobacteriaceae were highly susceptible (99.7%) to ceftazidime-avibactam, including 99.9% of metallo-␤-lactamase (MBL)-negative isolates; 87.4% of all P. aeruginosa isolates and 92.8% of MBL-negative isolates were susceptible to ceftazidime-avibactam. Susceptibility to ceftazidime-avibactam ranged from 99.4% to 100% for Enterobacteriaceae and from 79.1% to 94.7% for P. aeruginosa when isolates were analyzed by country of origin. Ceftazidime-avibactam inhibited 99.6% to 100% of Enterobacteriaceae isolates that carried serine ␤-lactamases, including extended-spectrum ␤-lactamases (ESBLs), AmpC cephalosporinases, and carbapenemases (KPC and OXA-48-like) as well as 99.7%, 99.6%, 99.5%, and 99.2% of MBL-negative isolatesdemonstratingceftazidime-nonsusceptible,multidrug-resistant(MDR),meropenem-nonsusceptible, and colistin-resistant phenotypes, respectively. Among carbapenem-nonsusceptible isolates of P. aeruginosa (n ϭ 750), 14.7% carried MBLs with or without additional acquired serine ␤-lactamases, while in the majority of isolates (70.0%), no acquired ␤-lactamase was identified. Ceftazidime-avibactam inhibited 89.5% of carbapenem-nonsusceptible P. aeruginosa isolates in which no acquired ␤-lactamase was detected. Overall, clinical isolates of Enterobacteriaceae collected in Latin America from 2012 to 2015 were highly susceptible to ceftazidime-avibactam, including isolates that exhibited resistance to ceftazidime, meropenem, colistin, or an MDR phenotype. Country-specific variations were noted in the susceptibility of P. aeruginosa isolates to ceftazidime-avibactam.

show abstract

Section: Discussionsupporting

confidence: 74%

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015

Karlowsky¹,

Kazmierczak²,

Bouchillon³

et al. 2019

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…1B ). Indeed, GES enzymes seem to be an important contributor to carbapenem resistance in P. aeruginosa from Mexico with a prevalence of 30.6% [11]. An analysis of the integron and surrounding genomic context revealed the Houston isolates possessed an OXA-2 β-lactamase and aminoglycoside modifying enzymes not present in the Mexican isolates ( Fig.…”

Section: Resultsmentioning

confidence: 99%

“…These enzymes are often found in association with class 1 integrons, a gene cassette acquisition system known to harbor multiple antimicrobial resistance determinants associated with mobile genetic elements [10]. A large percentage of carbapenem-resistant P.aeruginosa from Mexico have been associated with GES enzymes carried by class 1 integrons, with a study of isolates from Mexico City describing ST309 as a potential high risk clone [11, 12]. Here, we report the identification of two isolates of extremely drug-resistant P. aeruginosa ST309 causing bloodstream infections in unrelated patients and carrying simultaneously two variants of bla GES within a class 1 integron.…”

Section: Introductionmentioning

confidence: 99%

Extremely Drug-ResistantPseudomonas aeruginosaST309 Harboring Tandem GES Enzymes: A Newly Emerging Threat in the United States

Khan

Tran

Ríos

et al. 2019

Preprint

View full text Add to dashboard Cite

24 Two ST309 Pseudomonas aeruginosa clinical isolates resistant to carbapenems and 25 newer β-lactam/β-lactamase inhibitor combinations were found to harbor the extended 26 spectrum beta-lactamases GES 19 and 26 genetically clustered in tandem. The 27 combination of ceftazidime/avibactam plus aztreonam achieved cure in one patient. 28 Phylogenetic analysis suggests that ST309 P. aeruginosa carrying tandem GES are an 29 emerging lineage in the United States.

show abstract

“…GES-1 beta-lactamase was first detected in a Klebsiella pneumoniae isolate obtained in France in 1998 and subsequently detected in P. aeruginosa and other enterobacteriaceae from different geographical parts (Poirel et al, 2000;Garza-Ramos et al, 2015). The gene, blaGES-1, conferred an extendedspectrum cephalosporin resistance profile, including clavulanic acid (CA), tazobactam and imipenem (IPM).…”

Section: Introductionmentioning

confidence: 99%

Antibiotic susceptibility pattern of Pseudomonas aeruginosa expressing blaGES and blaPER genes in two different hospitals

Ahmed¹,

Asghar²

2017

Afr. J. Biotechnol.

View full text Add to dashboard Cite

Pseudomonas aeruginosa is intrinsically resistant to several antimicrobial drugs classes. Various extended-spectrum beta lactamases (ESBL) types have been found in P. aeruginosa such as Pseudomonas extended resistance (PER) and Guiana extended-spectrum (GES) enzymes. The study aimed to evaluate the susceptibility of the ESBL producing P. aeruginosa strains that express blaGES and blaPER genes to commonly used antibiotics. A total of 28 P. aeruginosa clinical isolates was identified as ESBL producers and subjected to polymerase chain reaction (PCR) technique for detection of blaGES, blaPER genes. Routine antimicrobial susceptibility was determined by the disc diffusion method. The highest resistance rate reached 71.4% for ciprofloxacin, while the lowest resistance rate (10.7%) was seen in imipenem followed by colistin (21.6%). blaGES gene was observed in 78.6% of the isolates, while blaPER appeared in 22.4%. It was concluded that imipenem and colistin showed good antipesuedomonal activity and blaGES was predominant gene among the ESBL producing P. aeruginosa in Makah hospitals. The results of the present study can help to prevent the mortality and morbidity associated with Pseudomonas infections in hospitals.

show abstract

Widespread of ESBL- and carbapenemase GES-type genes on carbapenem-resistant Pseudomonas aeruginosa clinical isolates: a multicenter study in Mexican hospitals

Cited by 43 publications

References 16 publications

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015

Extremely Drug-ResistantPseudomonas aeruginosaST309 Harboring Tandem GES Enzymes: A Newly Emerging Threat in the United States

Antibiotic susceptibility pattern of Pseudomonas aeruginosa expressing blaGES and blaPER genes in two different hospitals

Contact Info

Product

Resources

About